BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 23, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2003

View Archived Issues

Interim results for rAAT in otitis media

Read More

GSK researchers describe new Lp-PLA2 inhibitors and their use in atherosclerosis therapy

Read More

Heterocyclic PPAR agonists under study at Novartis

Read More

Schering AG claims new antiandrogen agents for prostate cancer and other uses

Read More

Bayer scientists discover novel alpha7 nAChR agonists with utility in cognition deficits

Read More

Azole compounds for diabetes, cancer and lipoprotein disorders claimed by Maxia

Read More

New series of chemokine CCR3 receptor modulators identified at BMS

Read More

Morphochem presents new tryptase and uPA inhibitors

Read More

Factor Xa inhibitors prepared and tested by Aventis researchers

Read More

Statistically significant imbalance in adverse events in Hemolink trial

Read More

Positive phase I results for EOquin support initiation of phase II testing

Read More

GSK and Pozen to develop and commercialize novel migraine treatment

Read More

Phase III program under way for once-weekly idraparinux

Read More

EMEA expands Zometa labeling

Read More

Dendreon's phase III trial will serve as basis for Provenge approval

Read More

FDA approval for Stalevo

Read More

Positive phase III topline results for Alprox-TD

Read More

Niaspan receives U.K. approval

Read More

Glucose- and triglyceride-lowering effects of a novel pan-PPAR agonist in ZDF rats

Read More

DRF-4832 improves hyperglycemia, hyperlipidemia, hypertension and atherosclerosis in animal models

Read More

Preclinical and clinical efficacy of MK-767, a dual PPARalpha/PPARgamma agonist

Read More

Preclinical activity of LY-519818, a PPARgamma-dominant agonist

Read More

Inhibition of glycogen phosphorylase/hepatic glycogenolysis as an approach to type 2 diabetes

Read More

Spotlight on melatonin

Read More

Long-term efficacy and safety results reported for lanthanum carbonate in chronic renal failure

Read More

Interferon alfa variants with enhanced immunomodulatory and antitumor activity

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing